SEC Company Response from GALECTIN THERAPEUTICS INC (GALT) (CIK 0001133416) (GALT) — Oct 8, 2010
GALECTIN THERAPEUTICS INC (GALT) (CIK 0001133416)
Date: Oct. 8, 2010 · CIK: 0001133416 · Accession: 0001193125-10-226344
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-31791
Letter
Via EDGAR Securities and Exchange Commission Division of Corporation Finance Attention: Tabatha Akins, Staff Accountant Re: Pro-Pharmaceuticals, Inc. Form 8-K Filed September 30, 2010 File No. 001-31791
Dear Ms Akins:
In response to your request in your comment letter, dated October 1, 2010, with respect to Pro-Pharmaceuticals, Inc. (the “Company” or “we”) Form 8-K Current Report, which was filed on September 30, 2010, and the Company’s response to your comment letter, dated October 6th, 2010, we acknowledge that:
•
The Company is responsible for the adequacy and accuracy of the disclosure in the filing;
•
Staff comment or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
•
The “Company” may not assert staff comment as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If you have any questions, please do not hesitate to contact me at (617) 559-0033 or on my cell at (603) 512-6593.
Sincerely,
/s/ Anthony Squeglia
Show Raw Text
CORRESP 1 filename1.htm Response Letter Pro-Pharmaceuticals, Inc. 7 Wells Avenue Newton, Massachusetts 02459 Via EDGAR October 8, 2010 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-4628 U.S.A. Attention: Tabatha Akins, Staff Accountant Re: Pro-Pharmaceuticals, Inc. Form 8-K Filed September 30, 2010 File No. 001-31791 Dear Ms Akins: In response to your request in your comment letter, dated October 1, 2010, with respect to Pro-Pharmaceuticals, Inc. (the “Company” or “we”) Form 8-K Current Report, which was filed on September 30, 2010, and the Company’s response to your comment letter, dated October 6th, 2010, we acknowledge that: • The Company is responsible for the adequacy and accuracy of the disclosure in the filing; • Staff comment or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and • The “Company” may not assert staff comment as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. If you have any questions, please do not hesitate to contact me at (617) 559-0033 or on my cell at (603) 512-6593. Sincerely, /s/ Anthony Squeglia Chief Financial Officer